FUCHS-PETROLUB-SE
15.11.2021 10:02:05 CET | Business Wire | Press release
The FUCHS Group, which operates globally in the lubricants industry, brings new small packs for the automotive sector onto the market, maximizing customer benefits: new labels for better orientation, ergonomic design for better handling, and gentle on resources thanks to the use of recycled material. The new small packs will be implemented gradually in the FUCHS companies from November 15, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005059/en/
The range of lubricant products in the automotive sector is enormous – and for customers it's getting harder and harder to find what they need. The new small packs for all automotive FUCHS product brands – TITAN, AGRIFARM, MAINTAIN, PLANTO, and SILKOLENE – rise to this challenge: The Group has optimized its small packs globally for the quantities 1, 4, and 5 liters, not just visually but also in terms of handling and environmental friendliness. "The unique new design makes it easier for our customers to choose the right product, improves user-friendliness, and saves on resources," sums up Krisztián Rada, Head of Automotive Aftermarket Division.
Easy to choose
The new clearly structured design of the labels enables customers to identify all the relevant information at a glance. Colors, images, and pictograms help with orientation. For instance, the quality levels of the products are clearly indicated by the color codes gold, silver, and bronze. The most important information the customer needs to know about the lubricant is given in concise and comprehensible way, such as the viscosity of the product and area of application – for cars, trucks, or tractors.
Easy to use
The new ergonomically shaped bottles are easy to open without tools, fit better in the hand, and are easier for the user to handle. For example, the enlarged opening of the bottle and an optimized neck design allow accurate filling with no drops. Two handles make the 4 and 5-liter bottles more comfortable to carry and facilitate filling. What's more, the new tamper-resistant cap ensures that the bottle has not been opened before and that if FUCHS is written on it, there is FUCHS inside it.
Easy on the environment :
FUCHS has been pursuing its sustainability strategy for almost ten years now, with the objective of carbon neutrality according to the "avoid – reduce – compensate" principle. As such, all FUCHS lubricants in the Group's plants are produced carbon-neutrally. The bottle material of the new small packs consists of up to 30 percent recycled material (PCR) and is 100-percent recyclable. The improved bottle shape of the bottle also makes it possible to pour out even the smallest remaining volume of fluid, allowing complete emptying of the bottles. "Our new small packs are not just intended to be more user-friendly but also contribute to avoiding waste, enable materials to be recycled, and help to reduce carbon footprints. FUCHS will continue to work toward making our packaging continuously more sustainable in the future, too," says Markus Garb, Vice President Sustainability, stating a further objective of the innovation.
The following information material is available online:
About FUCHS
FUCHS develops, produces and markets high-grade lubricants and related specialties for virtually all industries and areas of application. The company, which was founded in Mannheim in 1931, employs around 6,000 people worldwide at 58 operating companies. FUCHS is the world's largest independent lubricant manufacturer. The most important markets in terms of sales revenue are Western Europe, Asia and North America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005059/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
